What Alkermes Plc's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 8 | 33 |
| Total trades | 15 | 116 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 0 |
| Disposed | 0 | 0 |
| Net activity | +0 | +0 |
Common stock only — 116 reported trades in the last 12 months are in a security these totals do not cover.
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Reed Joshua | SVP, Chief Financial Officer | Oct 08 | Withheld — tax / exercise cost · F | −4,069 | $40.11 | −$163K | 5,095 |
| Reed Joshua | SVP, Chief Financial Officer | Oct 08 | Exercise / conversion · M | +9,164 | — | — | 9,164 |
| Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | Oct 02 | Open-market sale · S | −2,034 | $41.03 | −$83.5K | 221,388 |
| Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | Sep 03 | Open-market sale · S | −2,034 | $48.01 | −$97.7K | 223,422 |
| Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Sep 01 | Open-market sale · S | −9,000 | $46.99 | −$423K | 65,389 |
| Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Sep 01 | Exercise / conversion · M | +5,000 | $24.59 | +$123K | 74,389 |
| Nichols Christian Todd | SVP, Chief Commercial Officer | Aug 17 | Open-market sale · S | −664 | $49.65 | −$33K | 102,193 |
| Nichols Christian Todd | SVP, Chief Commercial Officer | Aug 17 | Open-market sale · S | −6,912 | $49.19 | −$340K | 102,857 |
| Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Aug 03 | Open-market sale · S | −9,000 | $48.58 | −$437K | 69,389 |
| Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Aug 03 | Exercise / conversion · M | +4,896 | $24.59 | +$120K | 78,389 |
| Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Aug 03 | Exercise / conversion · M | +104 | $19.34 | +$2.01K | 73,493 |
| Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | Aug 03 | Open-market sale · S | −2,034 | $48.58 | −$98.8K | 225,456 |
| snyderman nancy lynn Md | Director | Aug 03 | Open-market sale · S | −44,472 | $50.35 | −$2.24M | 15,395 |
| snyderman nancy lynn Md | Director | Aug 03 | Exercise / conversion · M | +16,524 | $46.72 | +$772K | 59,867 |
| snyderman nancy lynn Md | Director | Aug 03 | Exercise / conversion · M | +27,948 | $46.72 | +$1.31M | 43,343 |
| Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | Jul 06 | Open-market sale · S | −2,034 | $54.03 | −$110K | 227,490 |
| Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Jul 01 | Open-market sale · S | −700 | $52.13 | −$36.5K | 73,389 |
| Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Jul 01 | Open-market sale · S | −8,300 | $51.46 | −$427K | 74,089 |
| Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Jul 01 | Exercise / conversion · M | +5,000 | $19.34 | +$96.7K | 82,389 |
| Wright Christopher I | Director | Jun 12 | Open-market sale · S | −2,000 | $45.10 | −$90.2K | 25,680 |
Loading...
